Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5

Complement is a key component of the innate immune system. Inappropriate complement activation underlies the pathophysiology of a variety of diseases. Complement component 5 (C5) is a validated therapeutic target for complement-mediated diseases, but the development of new therapeutics has been limi...

Descripción completa

Detalles Bibliográficos
Autores principales: Latuszek, Adrianna, Liu, Yashu, Olsen, Olav, Foster, Randi, Cao, Marc, Lovric, Irena, Yuan, Ming, Liu, Nina, Chen, Henry, Zhang, Qian, Xiao, Hui, Springer, Carola, Ehrlich, George, Kamat, Vishal, Rafique, Ashique, Hu, Ying, Krueger, Pamela, Huang, Tammy, Poueymirou, William, Babb, Robert, Rosconi, Michael P., Retter, Marc W., Chen, Gang, Morton, Lori, Zambrowicz, Brian, Cao, Jingtai, Romano, Carmelo, Olson, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209288/
https://www.ncbi.nlm.nih.gov/pubmed/32384086
http://dx.doi.org/10.1371/journal.pone.0231892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209288/
https://www.ncbi.nlm.nih.gov/pubmed/32384086
http://dx.doi.org/10.1371/journal.pone.0231892

Ejemplares similares